New Oral AntiCoagulants Use in REnal Disease and AF (NOACURE-AF) Where do we stand?: An expert consensus view using the Delphi method

Arıcı, Mustafa; Ecder, Tevfik; Erdinler, İzzet; Ok, Ercan; Arıcan Özlük, Özlem; Türk, Uğur Önsel; Alioğlu, Emin

Journal Metrics

Impact Factor (2024): 0.9
CiteScore (2023): 1.3
Source Normalized Impact
per Paper:
0.315
SCImago Journal Rank: 0.250

52/7Current Issue Ahead of Print Archive Most Accessed Articles

Quick Search

In authors and

In titles and abstracts

In keywords

In all

New Oral AntiCoagulants Use in REnal Disease and AF (NOACURE-AF) Where do we stand?: An expert consensus view using the Delphi method [Turk Kardiyol Dern Ars]

Turk Kardiyol Dern Ars. 2021; 49(5): 345-352 | DOI: 10.5543/tkda.2021.40652

New Oral AntiCoagulants Use in REnal Disease and AF (NOACURE-AF) Where do we stand?: An expert consensus view using the Delphi method

Mustafa Arıcı¹, Tevfik Ecder², İzzet Erdinler³, Ercan Ok⁴, Özlem Arıcan Özlük⁵, Uğur Önsel Türk⁶, Emin Alioğlu⁶
¹Department of Nephrology, Hacettepe University School of Medicine, Ankara, Turkey
²Department of Nephrology, Demiroğlu Bilim University School of Medicine, İstanbul, Turkey
³Department of Cardiology, Memorial Ataşehir Hospital, İstanbul, Turkey
⁴Department of Nephrology, Ege University School of Medicine, İzmir, Turkey
⁵Department of Cardiology, Yüksek İhtisas Training and Research Hospital, Bursa, Turkey
⁶Department of Cardiology, İzmir Economy University School of Medicine, İzmir, Turkey

Keywords: Atrial fibrillation, non-vitamin K antagonist anticoagulants (NOACs), end-stage renal disease

Corresponding Author: Emin Alioğlu, Türkiye
Manuscript Language: English

CITE

Full Text PDF English Full Text Download citation RIS EndNote BibTex Medlars Procite Reference Manager Send email to author Similar articles PubMed Google Scholar